ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
RAPT Therapeutics Inc

RAPT Therapeutics Inc (RAPT)

3.31
-0.01
(-0.30%)
Closed June 17 4:00PM
3.31
0.00
( 0.00% )
Pre Market: 8:02AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
3.31
Bid
3.22
Ask
3.31
Volume
87
0.00 Day's Range 0.00
3.1701 52 Week Range 27.35
Market Cap
Previous Close
3.31
Open
-
Last Trade
5
@
3.28
Last Trade Time
08:06:57
Financial Volume
-
VWAP
-
Average Volume (3m)
814,549
Shares Outstanding
34,797,702
Dividend Yield
-
PE Ratio
-0.99
Earnings Per Share (EPS)
-3.36
Revenue
-
Net Profit
-116.8M

About RAPT Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RAPT. The last closing price for RAPT Therapeutics was $3.31. Over the last year, RAPT Therapeutics shares have traded in a share price range of $ 3.1701 to $ 27.35.

RAPT Therapeutics currently has 34,797,702 shares outstanding. The market capitalization of RAPT Therapeutics is $115.18 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.99.

RAPT Latest News

RAPT Therapeutics Reports First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.47-12.43386243393.783.953.17014921473.46480313CS
4-0.7-17.45635910224.014.833.17016192594.02626129CS
12-5.07-60.50119331748.389.65363.17018145496.23677825CS
26-16.31-83.12945973519.6227.353.1701101434910.0179555CS
52-16.7-83.458270864620.0127.353.170167696811.84093384CS
156-29.5-89.911612313332.8140.743.170145267518.02058399CS
260-8.94-72.979591836712.2551.20953.170139442120.94431549CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RELIReliance Global Group Inc
$ 0.602
(171.17%)
38.54M
NLSPNLS Pharmaceutics Ltd
$ 0.3671
(147.54%)
102.2M
ASNSActelis Networks Inc
$ 2.56
(122.61%)
19.77M
SNOASonoma Pharmaceuticals Inc
$ 0.2877
(70.74%)
43.21M
NUWENewellis Inc
$ 0.2818
(52.32%)
4.67M
STISolidion Technology Inc
$ 0.535
(-72.28%)
3.7M
DMTKDermTech Inc
$ 0.149
(-55.19%)
881.41k
AWINAERWINS Technologies Inc
$ 1.57
(-52.99%)
82.71k
BIOLBiolase Inc
$ 0.0888
(-40.24%)
7.7M
QMCOQuantum Corporation
$ 0.49
(-37.18%)
230.54k
NLSPNLS Pharmaceutics Ltd
$ 0.3671
(147.54%)
102.2M
MBIOMustang Bio Inc
$ 1.035
(38.00%)
44.54M
SNOASonoma Pharmaceuticals Inc
$ 0.2877
(70.74%)
43.21M
RELIReliance Global Group Inc
$ 0.6022
(171.26%)
38.54M
ASNSActelis Networks Inc
$ 2.56
(122.61%)
19.77M

RAPT Discussion

View Posts
Monksdream Monksdream 1 month ago
RAPT new 52 week
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
RAPT under $10
πŸ‘οΈ0
tickersym tickersym 4 months ago
Bargin prices!! Lets go!!
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 4 months ago
RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
πŸ‘οΈ0
StockLogistics StockLogistics 2 years ago
Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

β€œ8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
πŸ‘οΈ0
StockLogistics StockLogistics 2 years ago
12.16 gap fill over the next 14.5 weeks
πŸ‘οΈ0
StockLogistics StockLogistics 2 years ago
12.16 gap fill over the next 14.5 weeks
πŸ‘οΈ0
StockLogistics StockLogistics 2 years ago
15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.
πŸ‘οΈ0
StockLogistics StockLogistics 2 years ago
A ton of insider buying last week
πŸ‘οΈ0
StockLogistics StockLogistics 2 years ago
Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
πŸ‘οΈ0
Glider549 Glider549 3 years ago
It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.
πŸ‘οΈ0
weasel4339 weasel4339 3 years ago
It's way up after hours bud
πŸ‘οΈ0
Glider549 Glider549 3 years ago
Can't believe some of you did not take profits near the close.
Greed will kill ya.
πŸ‘οΈ0
pennyfinder pennyfinder 3 years ago
Will do
πŸ‘οΈ0
weasel4339 weasel4339 3 years ago
I'll keep n eye out. Let me knoe if u hear something about the price
πŸ‘οΈ0
pennyfinder pennyfinder 3 years ago
Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
πŸ‘οΈ0
weasel4339 weasel4339 3 years ago
This considered dilution?
πŸ‘οΈ0
pennyfinder pennyfinder 3 years ago
LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
πŸ‘οΈ0
make it happen make it happen 3 years ago
Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
πŸ‘οΈ0
pennyfinder pennyfinder 3 years ago
Offering AH or tomorrow pre
πŸ‘οΈ0
make it happen make it happen 3 years ago
Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M
πŸ‘οΈ0
StockLogistics StockLogistics 3 years ago
This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
πŸ‘οΈ0
Roadtojourney Roadtojourney 4 years ago
Not even 6 months old and already offering??
πŸ‘οΈ0
crudeoil24 crudeoil24 5 years ago
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
πŸ‘οΈ0
crudeoil24 crudeoil24 5 years ago
42.00 > hod.

RAPT
πŸ‘οΈ0
crudeoil24 crudeoil24 5 years ago
29.01 x 30.00

RAPT
πŸ‘οΈ0
crudeoil24 crudeoil24 5 years ago
Multiple Nasdaq circuit breakers halts today

RAPT
πŸ‘οΈ0
crudeoil24 crudeoil24 5 years ago
7.7M shares trading float >

RAPT
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock